Clinical Trial: A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503873) titled 'A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)' on March 09.

Brief Summary: The purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC with an AI device versus syringe.

Study Start Date: March 21

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis

Intervention: DRUG: Ublituximab

Administered as an SC injection by a syri...